The CRUK Cambridge Centre Thoracic Programme and the Early Cancer Institute are delighted to host this joint event.
The full-day Cambridge Symposium on Oesophageal Cancer takes place on Thursday 7 November 2024. Join us to learn about the latest fundamental, translational, and clinical advances in oesophageal cancer research.
Hear from world leaders in the field, including:
- Matthew Stachler Assistant Professor, Departments of Pathology and Laboratory Medicine, University of California San Fransisco
- Stuart McDonald Reader in Gastrointestinal Biology & Cancer Research UK Fellow, Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Rebecca Fitzgerald Professor of Cancer Prevention, Director Early Cancer Institute, University of Cambridge
- Trevor Graham Professor of Genomics and Evolution and the Director of the Centre for Evolution and Cancer, Institute of Cancer Research, London
- Paul Moss Professor of Haematology, Deputy Head of College of Medical and Dental Sciences, University of Birmingham
- Russell Petty Clinical Professor, Molecular and Clinical Medicine, University of Dundee
- Sarah Derks DR., (Principal Investigator), Amsterdam UMC and Oncode Institute, NL
- Steve Lin Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
- Karyn Goodman Professor and Vice Chair for Research and Quality, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York
- Yelena Janjigian Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Centre, New York
- Cindrilla Chumduri, Associate Professor, Meidcal Biotechnology, Department of Biological and Chemical Engineering, Aarhus University
Organising Committee: Prof. Rebecca Fitzgerald, Mr. J. Robert O’Neill, Dr. Massimilano di Pietro, Dr. Christopher Jones.
REGISTRATION
Registration is via Eventbrite at camsoc2024.eventbrite.co.uk
ABSTRACT SUBMISSION
We welcome abstracts from early career researchers and trainees for a chance to present a poster or short talk. Indicate your interest on the registration form or download the abstract submission form and instructions.
The deadline for submitting abstracts is 29 September 2024.
DRAFT SCHEDULE
A PDF version of the draft schedule is available to download.
08:30 - 09:00 Registration
09:00 - 11:00 SESSION 1 - Oesophageal carcinogenesis
- The past, present and future of early detection for oesophageal cancer - Rebecca Fitzgerald, Cambridge, UK
- Understanding what drives Barrett’s oesophagus progression for improved patient risk stratification - Matthew Stachler, UCSF, US
- Spatial analysis of the immune microenvironment reveals cellular neighbourhood alterations in Barrett’s oesophagus progression to cancer - Stuart McDonald, Barts, UK
- Presentation from Fiona Labrooy, COO at Heartburn Cancer UK
10:40 - 11:00 COFFEE BREAK
11:00 - 12:15 SESSION 2 - Understanding cancer development
- Decoding Fibroblast-Immune-Epithelial Crosstalk in Gastroesophageal Morphogenesis and Disease - Cindrilla Chumduri, Aarhus University, Denmark
- Evolutionary dynamics of Barrett’s Oesophagus leading to cancer - Trevor Graham, ICR, UK
12:15 - 13:15 LUNCH BREAK - Poster viewing / poster presentations
13:15 - 15:15 SESSION 3 - Treatment stratification and selection
- Optimising neoadjuvant CRT in ESO patients - Steven Lin, MD Anderson, US
- Spatial transcriptomic identifies lipid metabolism as dominant feature of T cell excluded oesophageal adenocarcinomas - Sarah Derks, Amsterdam UMC and Oncode Institute, Netherlands
- Optimising chemoradiotherapy for patients with oesophageal cancer: a tailored approach based on the CALGB 80803 study - Karyn Goodman, Mount Sinai, US
14:40 - 15:15 COFFEE BREAK
15:15 - 17:00 SESSION 4 - The immune microenvironment
- Talk Title TBC - Yelena Janjigian, MSKCC, US
- The immune microenvironment in oesophageal cancer and its relationship to treatment outcome - Paul Moss, Birmingham, UK
- Characterising and investigating the therapeutic potential of the oesophageal adenocarcinoma immunopeptidome in the PROTEAN study - Russell Petty, Dundee, UK